摘要
呼吸道合胞病毒（respiratory syncytial virus,RSV）是婴幼儿急性下呼吸道感染的首要原因.目前尚无RSV疫苗批准上市,手卫生和隔离是防止RSV传播的有效措施.帕利珠单抗能为高危婴儿提供安全、有效的被动预防,但非常昂贵.目前RSV感染仍主要依靠支持治疗.支气管扩张剂、糖皮质激素和白三烯拮抗剂等并未显示出决定性的疗效.利巴韦林也不常规用于治疗RSV感染.继续研发RSV疫苗和寻找更有效的抗病毒药物可能是未来预防和治疗RSV的方向.
Respiratory syncytial virus （RSV） is the leading cause of acute lower respiratory tract infections in infants and young children worldwide.Despite the magnitude of RSV disease,there remains no licensed vaccine product.Hand washing and isolation are highly effective in reducing the spread of RSV infection.Palivizumab can protect infants at high risk for RSV disease with safe and effective passive prophylaxis despite of the high costs.Treatment of RSV disease remains primarily supportive therapy.Clinical trials of bronchodilators,corticosteroids and leukotriene antagonists have not demonstrated conclusive benefit.The antiviral drug ribavirin is also not recommended for routine treatment of RSV infection.Future directions in treatment and prevention of RSV infections likely include the more potent antiviral compounds and the successful vaccination against RSV.
出处
《国际呼吸杂志》
2014年第10期776-780,共5页
International Journal of Respiration
关键词
呼吸道合胞病毒
预防
治疗
儿童
Respiratory syncytial virus
Prevention
Therapy
Child
